Table 3. Outcomes and immunosuppressive treatments after kidney transplantation, according to new onset AVN diagnosis (patients with pre-transplant AVN were excluded).

	Patients without AVN n = 773	NOAVN group n = 18	p
Follow-up duration, months [range]	64.7 [3–149.9]	55.2 [28.1–143.9]	0.85
Delayed graft function (%)	217 (28.1)	8 (44.4)	0.128
Acute rejection (TCMR and/or ABMR)
• At M3 (%)	55 (7.1)	5 (27.8)	0.008
• At M12 (%)	118 (15.7)	7 (38.9)	0.016
• At M24 (%)	138 (19.4)	7 (38.9)	0.065
Body mass index at M3 (kg/m2) (IQR1–IQR3)	24.6 (21.8–27.9)	26.9 (26.2–30.9)	0.003
Diabetes after transplantation (%)	311/702 (44.3)	10 (55.6)	0.35
Dyslipidemia after transplantation (%)	460/667 (69.0)	12 (66.7)	0.801
Immunosuppressive regimen at induction
• Anti-IL2 receptor antibody (%)	282 (36.6)	10 (55.6)	0.099
• Thymoglobulin (%)	451 (58.5)	8 (44.4)	0.23
• Cyclosporin (%)-Tacrolimus (%)	470 (61.3)-297 (38.7)	14 (77.8)-4 (22.2)	0.15
Corticosteroid dose (IQR1–IQR3)
• Oral cumulative dose at M3, mg	1758 (1348–2078)	2094 (2028–2105)	<0.001
• Bolus dose at M3, mg	500 (500–500)	500 (500–500)	0.73
• Total (oral + Bolus) dose at M3, mg	2035 (1675–2578)	2594 (2527–2605)	<0.001
• Oral cumulative dose at M12, mg	2280 (1680–3165)	3453 (3267–4314)	<0.001
• Bolus dose at M12, mg	500 (500–500)	500 (500–2000)	0.008
• Total (oral + Bolus) dose at M12, mg	2780 (2270–3928)	3970 (3767–6314)	<0.001
• Total (oral + Bolus) dose at M12, mg/kg	39.8 (32.3–56.4)	49.7 (44.5–67.9)	0.034
• Use of bolus after discharge in the first year (%)	116 (17.7)	7 (38.9)	0.011

Data are given as percentages or medians [minimum–maximum] or (interquartile IQR1–IQR3), as appropriate. AVN: avascular osteonecrosis; NOAVN: new Onset AVN; M3, M12, M24: 3, 12 and 24 post-transplant months; TCMR: T cell-mediated rejection; ABMR: antibody-mediated rejection